# A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Source: https://onco.cc/trials/nct01975701/  
OnCo record `nct01975701` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Infigratinib in Glioma & glioblastoma, run by Novartis Pharmaceuticals, completed.

## Summary

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM is a phase 2 interventional study registered as NCT01975701 by Novartis Pharmaceuticals, with 26 participants recorded, started 2013-12-09 and reaching its primary completion in 2018-10-03. Interventions recorded: BGJ398. Conditions recorded: Recurrent Glioblastoma or Other Glioma Subtypes.

Linked to the drug Infigratinib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01975701
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT01975701: https://clinicaltrials.gov/study/NCT01975701

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Infigratinib](https://onco.cc/drugs/infigratinib/)

---
JSON: https://onco.cc/api/v1/entities/nct01975701.json